Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris

American Journal of Cardiology

Volumn 80, Issue 4 B, 1997, Pages

  Alpert, Joseph S ^a,b,c,d,e,f   Bakx, Ad L M ^a,b,c,d,e,f   Braun, Shimon ^a,b,c,d,e,f   Frishman, William H ^a,b,c,d,e,f   Schneeweiss, Adam ^a,b,c,d,e,f   Tzivoni, Dan ^a,b,c,d,e,f   Kobrin, Isaac ^a,b,c,d,e,f  

^a UNIVERSITY OF ARIZONA   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e SHAARE ZEDEK MEDICAL CENTER   (Israel)

^f HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; GLYCERYL TRINITRATE; MIBEFRADIL; NITRATE; PLACEBO;

ADULT; ANGINA PECTORIS; ARTICLE; ATRIOVENTRICULAR BLOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; EXERCISE TOLERANCE; FEMALE; HEART MUSCLE ISCHEMIA; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS BRADYCARDIA;

EID: 0030801623     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00566-3     Document Type: Article

References (20)

1. Subramanian V, Bowles M, Khurmi N, Davies A, Raftery E. Rationale for the choice of calcium antagonists in chronic stable angina. An objective double-blind placebo-controlled comparison of nifedipine and verapamil. Am J Cardiol. 50:1982;1173-1179.
2. Frishman W, Charlap S, Kimmel B. Effects of diltiazem, nifedipine and their combination in transient ST-segment deviations on the ambulatory ECG in patients with stable angina pectoris. Circulation. 77:1988;774-786.
3. Clozel J-P, Banken L, Osterrieder W. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil. J Cardiovasc Pharmacol. 14:1989;713-721.
4. 2+ channel in cardiac tissue. Eur J Pharmacol. 290:1995;155-158.
5. 2+ channels by Ro 40-5967. Circ Res. 75:1994;144-148.
6. Clozel J-P, Osterrieder W, Kleinbloesem C, Welker HA, Schläppi B, Tudor R, Hefti F, Schmitt R, Eggers H. Ro 40-5967: a new non-dihydropyridine calcium antagonist. Cardiovasc Drug Rev. 9:1991;4-17.
7. Welker H, Eggers H, Kleinbloesem C, Erb K, Breithaupt K, Butzer R, Belz G. Ro 40-5967: pharmacokinetics of a new calcium antagonist. (Abstr.). Eur J Clin Pharmacol. 36:1989;A304.
8. Alpert JS, Kobrin I, DeQuattro V, Friedman R, Shepherd A, Fenster P. Additional anti-anginal and anti-ischemic efficacy of mibefradil in patients pretreated with a β-blocker for chronic stable angina pectoris. Am J Cardiol. 79:1997;1025-1030.
9. Bakx A, van der Wall E, Braun S, Emanuelsson H, Bruschke A, Kobrin I. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Am Heart J. 130:1995;748-757.
10. Braun S, van der Wall E, Emanuelsson H, Kobrin I. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. J Am Coll Cardiol. 27:1996;317-322.
11. Tzivoni D, Kadr H, Braat S, Rutsch W, Ramires J, Kobrin I. Efficacy of mibefradil in comparison to amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial. Circulation 1997; in press.
12. Kannel W. Some lessons in cardiovascular epidemiology from Framingham. Am J Cardiol. 37:1976;269-282.
13. Gillum R, Makuc D, Feldman J. Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic follow-up study. Am Heart J. 121:1991;172-177.
14. Perski A, Ollson G, Landou C, de Faire U, Theorell T, Hamsten A. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J. 123:1992;609-616.
15. Pepine C, Cohn P, Deedwania P, Gibson R, Handberg E, Hill J, Miller E, Marks R, Thadani U. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life: the Atenolol Silent Ischemia Study (ASIST). Circulation. 90:1994;762-768.
16. 3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther. 4:1990;731-736.
17. Su J, Renaud N, Carayon A, Crozatier B, Hittinger L. Effects of the calcium channel blockers, diltiazem and Ro 40-5967, on systemic haemodynamics and plasma noradrenaline levels in conscious dogs with pacing-induced heart failure. Br J Pharmacol. 13:1994;395-402.
18. Véniant M, Clozel J-P, Hess P, Wolfgang R. Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol. 17:1991;277-284.
19. Rousseau M, Hayashida W, van Eyll C, Hess O, Benedict C, Ahn S, Chapelle F, Kobrin I, Pouleur H. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocker, mibefradil, in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Cardiol. 28:1996;972-979.
20. Levine T. The design of the Mortality Assessment in Congestive Heart Failure trial (MACH-1, mibefradil). Clin Cardiol. 20:1997;320-326.